MX2020002036A - Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. - Google Patents
Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.Info
- Publication number
- MX2020002036A MX2020002036A MX2020002036A MX2020002036A MX2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A MX 2020002036 A MX2020002036 A MX 2020002036A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- associated antigen
- proteins binding
- binding nkg2d
- nkg2d
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 abstract 1
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549201P | 2017-08-23 | 2017-08-23 | |
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US201762558511P | 2017-09-14 | 2017-09-14 | |
| US201762558509P | 2017-09-14 | 2017-09-14 | |
| US201762558514P | 2017-09-14 | 2017-09-14 | |
| US201762566828P | 2017-10-02 | 2017-10-02 | |
| US201762581357P | 2017-11-03 | 2017-11-03 | |
| US201762608384P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/047714 WO2019040727A1 (en) | 2017-08-23 | 2018-08-23 | BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002036A true MX2020002036A (es) | 2020-03-24 |
Family
ID=65439284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002036A MX2020002036A (es) | 2017-08-23 | 2018-08-23 | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200231679A1 (enExample) |
| EP (1) | EP3672993A4 (enExample) |
| JP (2) | JP2020531525A (enExample) |
| KR (1) | KR20200038530A (enExample) |
| CN (1) | CN111315778A (enExample) |
| AU (1) | AU2018322178A1 (enExample) |
| BR (1) | BR112020003654A2 (enExample) |
| CA (1) | CA3072919A1 (enExample) |
| IL (2) | IL311488A (enExample) |
| MX (1) | MX2020002036A (enExample) |
| RU (1) | RU2020111554A (enExample) |
| SG (1) | SG11201913968VA (enExample) |
| WO (1) | WO2019040727A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| CN115298217A (zh) * | 2019-10-15 | 2022-11-04 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16及flt3的蛋白质 |
| US20230073946A1 (en) * | 2020-01-20 | 2023-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Affinity peptide conjugated with antioxidant for protection of proteins from oxidation |
| MX2022013944A (es) * | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CN114437214B (zh) * | 2020-11-03 | 2023-06-02 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| CN118812708B (zh) * | 2024-06-28 | 2025-04-04 | 北京普利米特生物科技有限公司 | 抗il-33抗体或其抗原结合片段及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1266014A2 (en) * | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP3587448B1 (en) * | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| EP3241561B1 (en) * | 2014-03-05 | 2025-04-30 | Autolus Limited | Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2 |
| JP2018503399A (ja) * | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| AU2016219785B2 (en) * | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048345A1 (en) * | 2015-12-28 | 2020-02-13 | Innate Pharma | Multispecific antigen binding proteins |
| CA3011535A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
-
2018
- 2018-08-23 MX MX2020002036A patent/MX2020002036A/es unknown
- 2018-08-23 RU RU2020111554A patent/RU2020111554A/ru unknown
- 2018-08-23 JP JP2020511319A patent/JP2020531525A/ja not_active Ceased
- 2018-08-23 US US16/639,150 patent/US20200231679A1/en not_active Abandoned
- 2018-08-23 WO PCT/US2018/047714 patent/WO2019040727A1/en not_active Ceased
- 2018-08-23 SG SG11201913968VA patent/SG11201913968VA/en unknown
- 2018-08-23 CN CN201880054953.2A patent/CN111315778A/zh active Pending
- 2018-08-23 AU AU2018322178A patent/AU2018322178A1/en not_active Abandoned
- 2018-08-23 KR KR1020207007908A patent/KR20200038530A/ko not_active Ceased
- 2018-08-23 IL IL311488A patent/IL311488A/en unknown
- 2018-08-23 CA CA3072919A patent/CA3072919A1/en active Pending
- 2018-08-23 EP EP18848423.2A patent/EP3672993A4/en not_active Withdrawn
- 2018-08-23 BR BR112020003654-4A patent/BR112020003654A2/pt not_active IP Right Cessation
-
2020
- 2020-02-16 IL IL272706A patent/IL272706A/en unknown
-
2023
- 2023-02-24 JP JP2023027219A patent/JP2023062184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200231679A1 (en) | 2020-07-23 |
| IL272706A (en) | 2020-04-30 |
| EP3672993A1 (en) | 2020-07-01 |
| CN111315778A (zh) | 2020-06-19 |
| CA3072919A1 (en) | 2019-02-28 |
| SG11201913968VA (en) | 2020-01-30 |
| RU2020111554A (ru) | 2021-09-23 |
| JP2023062184A (ja) | 2023-05-02 |
| BR112020003654A2 (pt) | 2020-11-17 |
| AU2018322178A1 (en) | 2020-02-20 |
| IL311488A (en) | 2024-05-01 |
| WO2019040727A1 (en) | 2019-02-28 |
| JP2020531525A (ja) | 2020-11-05 |
| KR20200038530A (ko) | 2020-04-13 |
| RU2020111554A3 (enExample) | 2022-01-19 |
| EP3672993A4 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002036A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. | |
| ZA201905462B (en) | Proteins binding her2, nkg2d and cd16 | |
| MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
| MX2020001257A (es) | Proteinas que se unen a nkg2d, cd16 y flt3. | |
| MX2019013998A (es) | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). | |
| MX2019009566A (es) | Proteinas de union a bcma, nkg2d y cd16. | |
| SA520420526B1 (ar) | Caix، بروتينات ربط متعددة النوعية تستهدف أوano1،أو ميسوثيلين، أوtrop2،أوcea، أو كلاودين-18.2 | |
| MX2019013995A (es) | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. | |
| EP4491234A3 (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| MX2022004430A (es) | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). | |
| MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
| MX2019009943A (es) | Proteínas que se unen a gd2, nkg2d y cd16. | |
| MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
| AU2018271930A1 (en) | A protein binding NKG2D, CD16 and a tumor-associated antigen | |
| MX2022013944A (es) | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MX2020002626A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores. | |
| AU2019415848A8 (en) | Claudin18.2 binding moieties and uses thereof | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| WO2019224716A8 (en) | Antibodies specific for gucy2c and uses thereof | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| EP4417263A3 (en) | Cd3 binding antibodies | |
| WO2019222449A8 (en) | Protein binding nkg2d, cd16 and a fibroblast activation protein | |
| ZA202301445B (en) | Proteins binding nkg2d, cd16 and egfr |